Yolife GmbH
Nightingale Health is a global leader in disease risk detection and preventative healthcare, providing advanced multi-disease health checks from a single blood sample.
About
Nightingale Health is a Finnish public healthcare technology company focused on transforming global healthcare with innovative disease risk detection solutions. Leveraging proprietary metabolomics and proteomics, Nightingale Health provides scalable blood tests that detect the risk of multiple chronic diseases, such as cardiovascular diseases, diabetes, kidney disease, liver diseases, and lung diseases, through a single blood sample. Their technology is adopted in both clinical and research settings, available for healthcare providers, insurance companies, governments, consumer health, telehealth, and medical research. The company’s mission is to build sustainable healthcare and reduce health inequalities worldwide by making preventative healthcare accessible and efficient. Nightingale Health operates internationally, with subsidiaries in Japan, the United States, Singapore, and the United Kingdom, serving customers in over 34 countries.
Products & Services
- Nightingale Health Check (multi-disease risk detection from a blood sample)
- Remote Health Check (at-home self-collected blood tests for chronic disease risk)
- Analysis services for medical research (multiomics, metabolomics, proteomics)
- Blood biomarker panel (advanced metabolic and proteomic analysis)
- Customized population-level screening solutions
- Integration of disease risk detection with insurance, government, and healthcare provider workflows
- Clinical-grade diagnostic blood values (e.g., cholesterol, glucose, creatinine, fatty acids, amino acids, inflammation markers, etc.)
Use Cases & Case Studies
- Case Terveystalo: Nationwide occupational and preventive health in Finland
- Adoption in South Savo and North Karelia Wellbeing Services Counties for public healthcare in Finland
- Population-level health risk screening in occupational and public health systems
- Improving early detection and prevention of chronic diseases in cohort studies (e.g., Aalborg University, Moli-sani study)
- Remote consumer health monitoring and telehealth integration
- Analysis of the world’s largest biobank cohorts
Partnerships & Collaborations
- Terveystalo (Finland's largest health service company)
- UK Biobank (world’s largest health research initiative)
- Aalborg University (multiomics provider for major research project in Denmark)
- Alamar Biosciences (integration of brain health proteomics)
- INM Neuromed for the Moli-sani study (Italy)
- Boston Heart Diagnostics (United States)
- Kaiser Foundation Health Plan, Inc.
- ZOE (nutrition and health research)
- 23andMe (pilot blood biomarker panel)
- Phenome Health (US-based health research)
- Enigma Genomics (Saudi Arabia and the MENA region)
- Innoquest Diagnostics (Southeast Asia)
Awards & Recognition
- Health Innovation of the Year
- Finnish Startup of the Year
- Best Health Tech Startup of the Year
- Paul Dudley White International Scholar Award from the American Heart Association
- Net Impact among the top 7 percent of companies globally
Contact Information
Certifications & Compliance
- CE marking for blood analysis technology (EU)
- ISO 13485:2016 (Singapore)
- UKCA mark (UK medical device compliance)
- New York State Clinical Laboratory Permit (CLEP, USA)
- Approved for healthcare use by Singapore's Health Sciences Authority (HSA)